Physician profile
Joseph Angelo
NPI 1740351147
$8,736.78
in general payments reported to CMS, 2019-2025
61 companies · $1,315 in 2025
The $1,315 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,429 · 2020: $374 · 2021: $1,345 · 2022: $1,531 · 2023: $1,349 · 2024: $1,393 · 2025: $1,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,997 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,996.79 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $836.48 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $670.58 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $652.02 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $615.73 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $596.49 | 2019-2025 | |
| Abbvie INC. | $525.19 | 2019-2025 | Qulipta, Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $455.18 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Esperion Therapeutics, INC. | $420.71 | 2021-2025 | Nexletol |
| Amgen INC. | $293.21 | 2019-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $246.71 | 2019-2025 | Spravato |
| Novartis Pharmaceuticals Corporation | $241.32 | 2019-2025 | |
| Amarin Pharma, INC. | $217.70 | 2019-2023 | |
| Antares Pharma, INC. | $171.39 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Abbott Laboratories | $169.57 | 2021-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $160.21 | 2023-2025 | Dexcom G6 Transmitter |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Angelo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.